ROLE OF MACROPHAGE RECEPTORS FOR OXLDL IN ATHEROGENESIS

OXLDL 巨噬细胞受体在动脉粥样硬化形成中的作用

基本信息

  • 批准号:
    6450713
  • 负责人:
  • 金额:
    $ 27.43万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-04-01 至 2002-03-31
  • 项目状态:
    已结题

项目摘要

The long term goal of the proposed studies is to improve our understanding of lipoprotein-macrophage interactions that may contribute to foam cell formation and atherogenesis. Emphasis will be placed on the acetyl LDL receptor (SRA), hCD36 and its mouse homologue (mDC36), and a 94-97 kDa oxidized LDL (OxLDL)- binding protein from mouse peritoneal macrophages which we have previously characterized and have now identified as macrosialin. Macrosialin and its human homologue, DC68, both previously clones, are found predominantly in the late endosomal fraction and their functions are not known. We propose to study their transport between subcellular compartment, to prepare stably transfected cells to characterize their ligand-binding properties, identify ligand binding sites by preparation of chimeric proteins and by site- directed mutagenesis, and prepare a mcarosialin knockout mouse to ascertain phenotypic consequences with regard to macrophage function, immune function and atherogenesis. CD36, an established OxLDL-binding receptor, functions in the binding and phagocytosis of apoptotic cells in cooperation with the vitronectin receptor and thrombospondin. We will test the hypothesis that binding of OxLDL may be modulated by interactions of this kind. Using cells from the SRA knockout mouse (gift of Dr. T. Kodama), we will assess the role of the receptor in OxLDL metabolism in vitro and in vivo. Finally, we will continue to use expression cloning in Xenopus oocytes to search for additional macrophage proteins that may participate in uptake of OxLDL or/and of damaged or apoptotic cells. Five clones have already been isolated. None of them represents either SRA, mCD36, or macrosialin. These will be sequenced and characterized.
拟议研究的长期目标是改善我们的

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DANIEL STEINBERG其他文献

DANIEL STEINBERG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DANIEL STEINBERG', 18)}}的其他基金

ROLE OF MACROPHAGE RECEPTORS FOR OXLDL IN ATHEROGENESIS
OXLDL 巨噬细胞受体在动脉粥样硬化形成中的作用
  • 批准号:
    6302476
  • 财政年份:
    2000
  • 资助金额:
    $ 27.43万
  • 项目类别:
ROLE OF MACROPHAGE RECEPTORS FOR OXLDL IN ATHEROGENESIS
OXLDL 巨噬细胞受体在动脉粥样硬化形成中的作用
  • 批准号:
    6110776
  • 财政年份:
    1999
  • 资助金额:
    $ 27.43万
  • 项目类别:
ROLE OF MACROPHAGE RECEPTORS FOR OXLDL IN ATHEROGENESIS
OXLDL 巨噬细胞受体在动脉粥样硬化形成中的作用
  • 批准号:
    6273232
  • 财政年份:
    1998
  • 资助金额:
    $ 27.43万
  • 项目类别:
ROLE OF MACROPHAGE RECEPTORS FOR OXLDL IN ATHEROGENESIS
OXLDL 巨噬细胞受体在动脉粥样硬化形成中的作用
  • 批准号:
    6242770
  • 财政年份:
    1997
  • 资助金额:
    $ 27.43万
  • 项目类别:
LIPIDS, LIPOPROTEINS AND ATHEROSCLEROSIS
脂质、脂蛋白和动脉粥样硬化
  • 批准号:
    2212185
  • 财政年份:
    1994
  • 资助金额:
    $ 27.43万
  • 项目类别:
LIPIDS, LIPOPROTEINS AND ATHEROSCLEROSIS
脂质、脂蛋白和动脉粥样硬化
  • 批准号:
    2212187
  • 财政年份:
    1994
  • 资助金额:
    $ 27.43万
  • 项目类别:
LIPIDS, LIPOPROTEINS AND ATHEROSCLEROSIS
脂质、脂蛋白和动脉粥样硬化
  • 批准号:
    2637547
  • 财政年份:
    1994
  • 资助金额:
    $ 27.43万
  • 项目类别:
LIPIDS, LIPOPROTEINS AND ATHEROSCLEROSIS
脂质、脂蛋白和动脉粥样硬化
  • 批准号:
    2212186
  • 财政年份:
    1994
  • 资助金额:
    $ 27.43万
  • 项目类别:
LIPIDS, LIPOPROTEINS AND ATHEROSCLEROSIS
脂质、脂蛋白和动脉粥样硬化
  • 批准号:
    2027290
  • 财政年份:
    1994
  • 资助金额:
    $ 27.43万
  • 项目类别:
ASPEN BILE ACID/CHOLESTEROL/LIPOPROTEIN CONFERENCE
阿斯彭胆汁酸/胆固醇/脂蛋白会议
  • 批准号:
    3435706
  • 财政年份:
    1991
  • 资助金额:
    $ 27.43万
  • 项目类别:

相似海外基金

TRANSLATIONAL REGULATION DURING XENOPUS OOCYTE DEVELOPMENT
非洲爪蟾卵母细胞发育过程中的翻译调控
  • 批准号:
    7610009
  • 财政年份:
    2007
  • 资助金额:
    $ 27.43万
  • 项目类别:
TRANSLATIONAL REGULATION DURING XENOPUS OOCYTE DEVELOPMENT
非洲爪蟾卵母细胞发育过程中的翻译调控
  • 批准号:
    7381391
  • 财政年份:
    2006
  • 资助金额:
    $ 27.43万
  • 项目类别:
CRYSTALLIZATION OF XENOPUS OOCYTE LECTIN
非洲爪蟾卵细胞凝集素的结晶
  • 批准号:
    6977733
  • 财政年份:
    2003
  • 资助金额:
    $ 27.43万
  • 项目类别:
CORE--ELECTROPHYSIOLOGY AND XENOPUS OOCYTE LABORATORY
核心--电生理学和爪蟾卵细胞实验室
  • 批准号:
    6575674
  • 财政年份:
    2002
  • 资助金额:
    $ 27.43万
  • 项目类别:
CORE--ELECTROPHYSIOLOGY AND XENOPUS OOCYTE LABORATORY
核心--电生理学和爪蟾卵细胞实验室
  • 批准号:
    6660036
  • 财政年份:
    2002
  • 资助金额:
    $ 27.43万
  • 项目类别:
CORE--ELECTROPHYSIOLOGY AND XENOPUS OOCYTE LABORATORY
核心--电生理学和爪蟾卵细胞实验室
  • 批准号:
    6441471
  • 财政年份:
    2001
  • 资助金额:
    $ 27.43万
  • 项目类别:
CORE--ELECTROPHYSIOLOGY AND XENOPUS OOCYTE LABORATORY
核心--电生理学和爪蟾卵细胞实验室
  • 批准号:
    6347434
  • 财政年份:
    2000
  • 资助金额:
    $ 27.43万
  • 项目类别:
UCP induction on the inner cell and mitochondrial membrances of Xenopus oocyte injected with gene transcripts from brown adipocytes of cold acclimated rat
注射冷驯化大鼠棕色脂肪细胞基因转录本的非洲爪蟾卵母细胞内细胞和线粒体膜上的 UCP 诱导
  • 批准号:
    12670069
  • 财政年份:
    2000
  • 资助金额:
    $ 27.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CORE--ELECTROPHYSIOLOGY AND XENOPUS OOCYTE LABORATORY
核心--电生理学和爪蟾卵细胞实验室
  • 批准号:
    6301309
  • 财政年份:
    2000
  • 资助金额:
    $ 27.43万
  • 项目类别:
CORE--ELECTROPHYSIOLOGY AND XENOPUS OOCYTE LABORATORY
核心--电生理学和爪蟾卵细胞实验室
  • 批准号:
    6106113
  • 财政年份:
    1999
  • 资助金额:
    $ 27.43万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了